ARS Pharma Q3 Revenue $37.7M, Net Loss Narrows to $35.6M; Breakeven Target Reaffirmed
SPRY is trading near its 52-week low of $2.59 (2.3% above the low).
Summary
ARS Pharma reported Q3 2026 revenue of $37.7M and a narrowed net loss of $35.6M, with SG&A down sharply and cash flow breakeven still targeted for year-end 2027.
Key Events · Earnings and Guidance · SPRY
-
Q3 Revenue Grows to $37.7M
Total revenue was $37.7M versus $32.5M a year earlier, including $33.4M of U.S. net product revenue for neffy.
-
Net Loss Narrows on Cost Cuts
Net loss fell to $35.6M, or $(0.36) per share, from $51.2M, or $(0.52) per share, as SG&A dropped to $43.5M from $74.8M.
-
Market Share Still Modest
Total U.S. neffy market share reached 5%, up from 4%, and about 9% in field-targeted accounts versus 2% in non-targeted accounts.
-
Breakeven Target Reaffirmed
With $138.4M in cash, cash equivalents and short-term investments at September 30, 2026, the company still expects cash flow breakeven by the end of 2027.
Analysis · SPRY · Life Sciences
Revenue grew to $37.7M from $32.5M a year ago, but the more important number is on the cost side: SG&A fell to $43.5M from $74.8M after the company pulled back on linear TV and broad consumer advertising. That cut the quarterly net loss to $35.6M from $51.2M and keeps management's year-end 2027 cash flow breakeven target intact on $138.4M of cash and short-term investments. The offset is growth: neffy's total U.S. market share is only 5%, up from 4% a year ago, and the new commercial chief is shifting to account-based targeting. With the stock near its 52-week low of $2.59, the market is already pricing skepticism about the growth story; cost discipline is what protects the runway while that strategy is tested.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRY was trading at $2.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $263.5M. The 52-week trading range was $2.59 to $13.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.